| Date | Title | Description |
| 16.06.2025 | Wall Street recovers from Friday’s shock as US stocks rise and oil prices ease | Iran’s foreign minister, Abbas Araghchi, appeared to make a veiled outreach for the U.S. to step in and negotiate an end to hostilities between Israel and Iran, saying in a post on X that a phone call from Washington to Israel’s leader “may... |
| 25.02.2025 | The Future of Advanced Therapeutics: Opportunities and Challenges | Sai Bhamidipati, Pharmaceutical Regulatory Affairs Consultant
The biopharmaceutical landscape is transforming with the advent of advanced therapeutics, including mRNA vaccines, gene therapies, and personalized medicine. These innovative tre... |
| 11.01.2025 | Biogen proposes to buy remaining stake in Sage in $442 million deal | Biogen proposes to buy remaining stake in Sage in $442 million deal
By ReutersJanuary 10, 202511:39 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Biogen logo is seen displayed in this illustra... |
| 09.10.2024 | City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine | City Therapeutics announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. And City Therapeutics aims to utilize next-generation engineering of small interfering RNAs (siRNAs) – which is the “trigger”... |
| 15.09.2024 | SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit | NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the "... |
| 31.08.2024 | SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit | NEW YORK, Aug. 31, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021... |
| 24.04.2024 | DATAcc by DiMe Launches Core Measures for Sleep | Core sleep measures and resources will help transform sleep research and care to advance the treatment of multiple disease areas
BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) b... |
| 06.02.2023 | Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD)
Depression is a public health issue with significant unmet medical need
... |
| 27.10.2021 | Enjoy The Journey: The Need For A Talent Brand | Erin Lanciani, Chief People & Experience Officer, Sage Therapeutics. |
| 19.10.2021 | 15 Ways Hiring Managers Can Ensure Value Alignment With Prospective Employees | Workplace culture and company values have become an increasingly important job consideration for both candidates and hiring managers. Companies and employees alike want to find a mutual fit and ensure everyone on the team is operating under... |
| 15.06.2021 | Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder | At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo
Rapid onset of treatment effect was seen in... |
| 17.03.2021 | Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 17, 2021--
Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-label SHORELINE Study. T... |
| 31.12.2020 | Sage Therapeutics, Inc. announced that it has received $649.986998 million in funding from Biogen MA Inc. | On December 31, 2020, Sage Therapeutics, Inc. (NasdaqGM:SAGE) closed the transaction. The company raised $649,986,998 pursuant to Regulation D. |
| 05.12.2019 | Sage Therapeutics’ stock tanks as Phase III depression study misses primary endpoint | Shares of a company developing a drug to treat depression dropped sharply Thursday following the announcement that its registration-directed clinical trial had missed its primary endpoint.
Cambridge, Massachusetts-based Sage Therapeutics sa... |
| 31.10.2016 | Third Rock Ventures closes $616 million healthcare fund | Fund IV has not yet begun investing, according to a company representative, but the firm has established a strong track record with its first three funds. In less than 10 years, Third Rock has invested in 40 companies, advancing 40 clinical... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 13.03.2014 | SAGE Therapeutics Closes $38M in Series C |
CAMBRIDGE, MA, Biopharmaceutical company developing novel medicines announced the successful completion of a $38 million Series C financing.
>> Click here for more funding data on SAGE Therapeutics
>> To export SAGE Therapeu... |
| 13.03.2014 | SAGE Therapeutics Completes $38M Series C Financing | SAGE Therapeutics, a Cambridge, MA-based biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, completed a $38m Series C financing.
Backers included OrbiMed Advi... |
| 16.10.2013 | SAGE Therapeutics Secures $20M in Series B |
CAMBRIDGE, MA, Biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced a $20 million Series B financing.
>> Click here for more funding data on SAGE Therapeutics
>>... |
| 16.10.2013 | Sage Therapeutics Raises $20m in Series B Financing | Sage Therapeutics, a Cambridge, MA-based biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, raised $20m in Series B financing.
Backers included ARCH Venture Partners and Third Rock Ventures.... |
| 17.04.2013 | Sage Therapeutics Shifts Gears, Focuses on Rare Form of Epilepsy | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Sometimes it takes a little time, and a little luck for a company to find its identity. Of course, when you’re a biotech like Cambridge, MA-based Sage Therapeutics, it doesn’t... |
| 14.06.2012 | Venture firm launches rare blood disorder therapeutics developer with $41M | Among the company’s founders are three scientific researchers from University of California, San Francisco: Dr. Matthew Jacobson, Dr. Andrej Sali and Dr. Jack Taunton, and two Third Rock directors: Dr. Charles Homcy and Craig Muir. Dr. Mark... |
| 18.10.2011 | SAGE Therapeutics Launches With $35 million Series A |
SAGE Teams with CNS Expert Steven Paul, M.D.; Secures $35 million Series A to Accelerate Treatments for CNS Conditions; Expects to Launch First of Several Clinical Programs in 2012.
>> Click here for more funding data on SAGE Thera... |
| 18.10.2011 | SAGE Therapeutics Raises $35M in Series A Funding from Third Rock Ventures | SAGE Therapeutics, a Boston, MA-based newly formed company that focuses on building central nervous system (CNS) products, has raised $35m in Series A funding from Third Rock Ventures.
Founded by Steven Paul, M.D., the former executive vice... |
| - | Sage Therapeutics Announces Departure of Chief Operating Officer | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 16, 2021--
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, t... |
| - | Third Rock Ventures closes $616 million healthcare fund | Third Rock Ventures announced Monday that it had closed its fourth fund — it’s largest, Third Rock Ventures IV — for an oversubscribed $616 million.
The Boston, Massachusetts-based firm now has a total of $1.9 billion in assets under manage... |
| - | Sage Therapeutics’ stock tanks as Phase III depression study misses primary endpoint | Shares of a company developing a drug to treat depression dropped sharply Thursday following the announcement that its registration-directed clinical trial had missed its primary endpoint.
Cambridge, Massachusetts-based Sage Therapeutics sa... |
| - | Venture firm launches rare blood disorder therapeutics developer with $41M | Venture capital firm Third Rock Ventures has launched a drug development startup to treat genetic blood disorders, with sickle-cell anemia as its lead program target, providing $40.7 million in series A financing.
Global Blood Therapeutics‘... |
| - | Sage Therapeutics to Present at the Stifel 3rd Annual CNS Day | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 24, 2021--
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of... |
| - | Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2021--
Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disor... |
